Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
4.595
-0.075 (-1.61%)
Aug 12, 2026, 3:05 PM EDT - Market open
Arbutus Biopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 181.72 | 14.08 | 6.17 | 18.14 | 39.02 | 10.99 | |
Revenue Growth | 1078.78% | 128.21% | -65.98% | -53.51% | 255.11% | 58.92% |
Gross Profit | 181.72 | 14.08 | 6.17 | 18.14 | 39.02 | 10.99 |
Selling, General & Admin | 16.49 | 15.89 | 22.11 | 22.48 | 17.83 | 17.14 |
Research & Development | 17.8 | 25.24 | 54.04 | 73.7 | 84.41 | 65.5 |
Other Operating Expenses | -1.57 | 11.11 | 6.35 | 0.07 | 2.23 | 1.87 |
Total Operating Expenses | 32.73 | 52.24 | 82.49 | 96.24 | 104.48 | 84.51 |
Operating Income | 149 | -38.16 | -76.32 | -78.1 | -65.46 | -73.52 |
Interest Income | 3.49 | 4.07 | 6.59 | 5.69 | 2.19 | 0.13 |
Interest Expense | -0.08 | -0.1 | -0.14 | -0.46 | -1.73 | -2.86 |
Other Non-Operating Income (Expense) | -0.03 | 0.69 | -0.05 | 0.03 | -0.02 | 0.01 |
Total Non-Operating Income (Expense) | 4.06 | 4.66 | 6.4 | 5.25 | 0.44 | -2.73 |
Pretax Income | 153.05 | -33.5 | -69.92 | -72.85 | -65.01 | -76.25 |
Provision for Income Taxes | - | - | - | - | -4.44 | - |
Net Income | 153.05 | -33.5 | -69.92 | -72.85 | -69.46 | -76.25 |
Net Income to Common | 153.05 | -33.5 | -69.92 | -72.85 | -69.46 | -88.39 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 194 | 192 | 186 | 166 | 151 | 106 |
Shares Outstanding (Diluted) | 194 | 192 | 186 | 166 | 151 | 106 |
Shares Change | 1.97% | 3.23% | 11.84% | 9.95% | 42.07% | 40.10% |
EPS (Basic) | 0.80 | -0.17 | -0.38 | -0.44 | -0.46 | -0.83 |
EPS (Diluted) | 0.79 | -0.17 | -0.38 | -0.44 | -0.46 | -0.83 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -24.63 | -39.64 | -65.03 | -86.94 | -35.87 | -68.34 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Per Share | -0.13 | -0.21 | -0.35 | -0.52 | -0.24 | -0.64 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | 81.99% | -270.96% | -1236.74% | -430.53% | -167.75% | -669.11% |
Profit Margin | 84.23% | -237.88% | -1133.04% | -401.57% | -178.01% | -693.91% |
FCF Margin | -13.55% | -281.45% | -1053.83% | -479.27% | -91.92% | -621.96% |
EBITDA | 149.04 | -37.8 | -74.94 | -76.7 | -64.03 | -71.77 |
EBITDA Margin | 82.02% | -268.39% | -1214.37% | -422.79% | -164.10% | -653.16% |
EBIT | 149 | -38.16 | -76.32 | -78.1 | -65.46 | -73.52 |
EBIT Margin | 81.99% | -270.96% | -1236.74% | -430.53% | -167.75% | -669.11% |
Effective Tax Rate | - | 0.00% | 0.00% | 0.00% | 6.84% | 0.00% |